Pricing Log in Create free account
Friday 6 November 2026 Export ARWR’s income statement to Excel — free account

Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.

Revenue
+171.0%
EPS
−7.94%
Free cash flow
−15.4%
Total debt
+259.5%

Quarter to June 2026, against a year earlier

58.07 0.61 +1.06%
Market cap
$8.1B
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Arrowhead Pharmaceuticals, Inc. 8-K filed Nov 29, 2023

Period ended Nov 29, 2023 · Filed · accepted 4:10 PM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release